Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI

被引：0
|
作者：
Vasile, E. [1 ]
Masi, G. [1 ]
Loupakis, F. [1 ]
Cupini, S. [1 ]
Baldi, G. G. [1 ]
Salvatore, L. [1 ]
Fornaro, L. [1 ]
Pfanner, E. [2 ]
Ricci, S. [2 ]
Falcone, A. [1 ]
机构：
[1] Univ Pisana, Dipartimento Interaziendale Oncol Med, Azienda Osped, Ist Toscano Tumori,Azienda USL Livorno 6, Pisa, Italy
[2] Univ Pisana, UO Oncol Med 1, Azienda Osped, Ist Toscano, Pisa, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71175-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [1] REINTRODUCTION OF FOLFOXIRI TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Baldi, Giacomo Giulio
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Stasi, Irene
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [2] Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Fornaro, L.
    Salvatore, L.
    Cupini, S.
    Stasi, I.
    Brunetti, I. M.
    Andreuccetti, M.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 347
  • [3] SECOND-LINE TREATMENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Fornaro, Lorenzo
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Stasi, Irene
    Baldi, Giacomo Giulio
    Cupini, Samanta
    Barbara, Cecilia
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Chiara, Silvana
    Vitello, Stefano
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [4] FOLFOXIRI reintroduction in metastatic colorectal cancer
    Glynne-Jones, Rob
    Harrison, Mark
    [J]. LANCET ONCOLOGY, 2020, 21 (04): : 468 - 469
  • [5] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [6] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [7] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Kito, Yosuke
    Satake, Hironaga
    Taniguchi, Hiroya
    Yamada, Takeshi
    Horie, Yoshiki
    Esaki, Taito
    Denda, Tadamichi
    Yasui, Hisateru
    Izawa, Naoki
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Mori, Keita
    Yamazaki, Kentaro
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
  • [9] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Yosuke Kito
    Hironaga Satake
    Hiroya Taniguchi
    Takeshi Yamada
    Yoshiki Horie
    Taito Esaki
    Tadamichi Denda
    Hisateru Yasui
    Naoki Izawa
    Toshiki Masuishi
    Toshikazu Moriwaki
    Keita Mori
    Kentaro Yamazaki
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
  • [10] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
12345